Relapse of Paragonimus Westermani Lung Infection After Bithionol Therapy

David L. ColemanInfectious Disease and General Medicine Sections, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510

Search for other papers by David L. Coleman in
Current site
Google Scholar
PubMed
Close
and
Michele BarryInfectious Disease and General Medicine Sections, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06510

Search for other papers by Michele Barry in
Current site
Google Scholar
PubMed
Close
Restricted access

Clinical trials of bithionol in treating Paragonimus westermani lung infection have been conducted in areas of endemic infection. Bithionol has been reported to cure over 90% of infected patients. We report a case of a 32-year-old Laotian man residing in Connecticut who relapsed with P. westermani pneumonitis 4 months after apparent eradication of infection with bithionol (40 mg/kg by mouth every other day for 10 doses). He was successfully treated with a second course of bithionol (40 mg/kg by mouth every other day for 15 doses). The mechanism of relapse of P. westermani infection following bithionol therapy should be evaluated.

Save